Abstract: The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

Abstract: The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.

Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents. Other embodiments relate to pharmaceutical compositions containing boronic acid derivatives and additional excipient such as meglumine.

Abstract: The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

Abstract: The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.

Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronate compounds and their use as therapeutic agents.

Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronate compounds and their use as therapeutic agents.

Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents. Other embodiments relate to pharmaceutical compositions containing boronic acid derivatives and additional excipient such as meglumine.

Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.

Abstract: The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

Abstract: Various exemplary embodiments relate to a temperature compensation structure for use in a dielectric resonator that permits a support to be thermally efficient in rapidly transferring heat generated by a central puck in the resonator. The temperature compensation structure may have an extension shaped to promote heat from the puck into the support, thereby permitting high power operation of the dielectric resonator without overheating.

Abstract: Various exemplary embodiments relate to an improved coupler for resonant cavities and dielectric resonators. The coupler may permit accurate tuning of electromagnetic signals within desired frequency ranges. The coupler may be secured to a movable tuning device by a plurality of securing members. Each securing member may be separate, having no contact with any other securing member.

Abstract: Various exemplary embodiments include a cavity having a tuning assembly with tunable capacitive coupling. The tuning assembly may have a recess having a specified depth, designed for a default magnitude of coupling into the cavity. A sleeve may be fully inserted within the recess to have the structure operate at that default coupling magnitude. If a different amount of coupling is desired, the sleeve may be inserted to a particular depth that only includes part of the recess, enabling repeatable tuning of a plurality of cavities.

Abstract: Various exemplary embodiments relate to a temperature compensation structure for use in a dielectric resonator that permits a support to be thermally efficient in rapidly transferring heat generated by a central puck in the resonator. The temperature compensation structure may have an extension shaped to promote heat from the puck into the support, thereby permitting high power operation of the dielectric resonator without overheating.

Abstract: Various exemplary embodiments relate to an improved coupler for resonant cavities and dielectric resonators. The coupler may permit accurate tuning of electromagnetic signals within desired frequency ranges. The coupler may be secured to a movable tuning device by a plurality of securing members. Each securing member may be separate, having no contact with any other securing member.

Abstract: Various exemplary embodiments include a cavity having a tuning assembly with tunable capacitive coupling. The tuning assembly may have a recess having a specified depth, designed for a default magnitude of coupling into the cavity. A sleeve may be fully inserted within the recess to have the structure operate at that default coupling magnitude. If a different amount of coupling is desired, the sleeve may be inserted to a particular depth that only includes part of the recess, enabling repeatable tuning of a plurality of cavities.